Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 305

1.

The histopathology of myeloma in the bone marrow.

Fujino M.

J Clin Exp Hematop. 2018;58(2):61-67. doi: 10.3960/jslrt.18014. Review.

2.

Evaluation of high-dose cytarabine in induction therapy for children with de novo acute myeloid leukemia: a study protocol of the Japan Children's Cancer Group Multi-Center Seamless Phase II-III Randomized Trial (JPLSG AML-12).

Tomizawa D, Tanaka S, Hasegawa D, Iwamoto S, Hiramatsu H, Kiyokawa N, Miyachi H, Horibe K, Saito AM, Taga T, Adachi S.

Jpn J Clin Oncol. 2018 Jun 1;48(6):587-593. doi: 10.1093/jjco/hyy061.

PMID:
29889285
3.

Durable Remissions with Ivosidenib in IDH1-Mutated Relapsed or Refractory AML.

DiNardo CD, Stein EM, de Botton S, Roboz GJ, Altman JK, Mims AS, Swords R, Collins RH, Mannis GN, Pollyea DA, Donnellan W, Fathi AT, Pigneux A, Erba HP, Prince GT, Stein AS, Uy GL, Foran JM, Traer E, Stuart RK, Arellano ML, Slack JL, Sekeres MA, Willekens C, Choe S, Wang H, Zhang V, Yen KE, Kapsalis SM, Yang H, Dai D, Fan B, Goldwasser M, Liu H, Agresta S, Wu B, Attar EC, Tallman MS, Stone RM, Kantarjian HM.

N Engl J Med. 2018 Jun 21;378(25):2386-2398. doi: 10.1056/NEJMoa1716984. Epub 2018 Jun 2.

PMID:
29860938
4.

Asymmetric and symmetric dimethylarginines and mortality in patients with hematological malignancies-A prospective study.

Chachaj A, Wiśniewski J, Rybka J, Butrym A, Biedroń M, Krzystek-Korpacka M, Fleszar MG, Karczewski M, Wróbel T, Mazur G, Gamian A, Szuba A.

PLoS One. 2018 May 22;13(5):e0197148. doi: 10.1371/journal.pone.0197148. eCollection 2018.

5.

Gemtuzumab ozogamicin for the treatment of acute myeloid leukemia.

Baron J, Wang ES.

Expert Rev Clin Pharmacol. 2018 Jun;11(6):549-559. doi: 10.1080/17512433.2018.1478725. Epub 2018 Jun 11. Review.

PMID:
29787320
6.

Early changes in rpS6 phosphorylation and BH3 profiling predict response to chemotherapy in AML cells.

Grundy M, Jones T, Elmi L, Hall M, Graham A, Russell N, Pallis M.

PLoS One. 2018 May 3;13(5):e0196805. doi: 10.1371/journal.pone.0196805. eCollection 2018.

7.

The influence of mutational status and biological characteristics of acute myeloid leukemia on xenotransplantation outcomes in NOD SCID gamma mice.

Culen M, Kosarova Z, Jeziskova I, Folta A, Chovancova J, Loja T, Tom N, Bystry V, Janeckova V, Dvorakova D, Mayer J, Racil Z.

J Cancer Res Clin Oncol. 2018 Jul;144(7):1239-1251. doi: 10.1007/s00432-018-2652-2. Epub 2018 May 2.

PMID:
29721667
8.

A new intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in patients with refractory or relapsed acute myeloid leukemia.

Wang J, Zhao J, Fei X, Yin Y, Cheng H, Zhang W, Gu J, Yang F, Yang Y, Xue S, Tian Z, He J, Zhang S, Wang X.

Medicine (Baltimore). 2018 Apr;97(17):e0228. doi: 10.1097/MD.0000000000010228.

9.

Advancements in the management of medically less-fit and older adults with newly diagnosed acute myeloid leukemia.

Michaelis LC, Klepin HD, Walter RB.

Expert Opin Pharmacother. 2018 Jun;19(8):865-882. doi: 10.1080/14656566.2018.1465562. Epub 2018 Apr 26. Review.

PMID:
29697000
10.

BAALC and ERG expression levels at diagnosis have no prognosis impact on acute myeloid leukemia patients undergoing allogeneic hematopoietic stem cell transplantation.

Zhang J, Shi J, Zhang G, Zhang X, Yang X, Yang S, Wang J, Ke X, Fu L.

Ann Hematol. 2018 Aug;97(8):1391-1397. doi: 10.1007/s00277-018-3331-8. Epub 2018 Apr 25.

PMID:
29696374
11.

Implications of Mutation Profiling in Myeloid Malignancies-PART 1: Myelodysplastic Syndromes and Acute Myeloid Leukemia.

Tremblay D, Sokol K, Bhalla S, Rampal R, Mascarenhas JO.

Oncology (Williston Park). 2018 Apr 15;32(4):e38-e44. Review.

12.

Salvage regimens using conventional chemotherapy agents for relapsed/refractory adult AML patients: a systematic literature review.

Megías-Vericat JE, Martínez-Cuadrón D, Sanz MÁ, Montesinos P.

Ann Hematol. 2018 Jul;97(7):1115-1153. doi: 10.1007/s00277-018-3304-y. Epub 2018 Apr 21. Review.

PMID:
29680875
13.

Long non-coding RNA taurine-upregulated gene 1 correlates with poor prognosis, induces cell proliferation, and represses cell apoptosis via targeting aurora kinase A in adult acute myeloid leukemia.

Wang X, Zhang L, Zhao F, Xu R, Jiang J, Zhang C, Liu H, Huang H.

Ann Hematol. 2018 Aug;97(8):1375-1389. doi: 10.1007/s00277-018-3315-8. Epub 2018 Apr 13.

PMID:
29654398
14.

Prolonged granulocyte colony stimulating factor use in glycogen storage disease type 1b associated with acute myeloid leukemia and with shortened telomere length.

Li AM, Thyagu S, Maze D, Schreiber R, Sirrs S, Stockler-Ipsiroglu S, Sutherland H, Vercauteren S, Schultz KR.

Pediatr Hematol Oncol. 2018 Feb;35(1):45-51. doi: 10.1080/08880018.2018.1440675. Epub 2018 Apr 13.

PMID:
29652549
15.

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up.

Boyer T, Gonzales F, Plesa A, Peyrouze P, Barthelemy A, Guihard S, Quesnel B, Roumier C, Preudhomme C, Cheok M.

J Vis Exp. 2018 Mar 26;(133). doi: 10.3791/56976.

PMID:
29630051
16.

Splenic tyrosine kinase (SYK) inhibitors and their possible use in acute myeloid leukemia.

Bartaula-Brevik S, Lindstad Brattås MK, Tvedt THA, Reikvam H, Bruserud Ø.

Expert Opin Investig Drugs. 2018 Apr;27(4):377-387. doi: 10.1080/13543784.2018.1459562. Epub 2018 Apr 4. Review.

PMID:
29611449
17.

An efficient strategy for identifying cancer-related key genes based on graph entropy.

Zhang W, Wang SL.

Comput Biol Chem. 2018 Jun;74:142-148. doi: 10.1016/j.compbiolchem.2018.03.022. Epub 2018 Mar 21.

PMID:
29609142
18.

Pharmacokinetics-adapted Busulfan-based myeloablative conditioning before unrelated umbilical cord blood transplantation for myeloid malignancies in children.

Benadiba J, Ansari M, Krajinovic M, Vachon MF, Duval M, Teira P, Cellot S, Bittencourt H.

PLoS One. 2018 Apr 2;13(4):e0193862. doi: 10.1371/journal.pone.0193862. eCollection 2018.

19.

Molecular Minimal Residual Disease in Acute Myeloid Leukemia.

Jongen-Lavrencic M, Grob T, Hanekamp D, Kavelaars FG, Al Hinai A, Zeilemaker A, Erpelinck-Verschueren CAJ, Gradowska PL, Meijer R, Cloos J, Biemond BJ, Graux C, van Marwijk Kooy M, Manz MG, Pabst T, Passweg JR, Havelange V, Ossenkoppele GJ, Sanders MA, Schuurhuis GJ, Löwenberg B, Valk PJM.

N Engl J Med. 2018 Mar 29;378(13):1189-1199. doi: 10.1056/NEJMoa1716863.

PMID:
29601269
20.

Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.

Li Y, Zhang M, Sheng M, Zhang P, Chen Z, Xing W, Bai J, Cheng T, Yang FC, Zhou Y.

J Cancer Res Clin Oncol. 2018 Jun;144(6):1065-1077. doi: 10.1007/s00432-018-2631-7. Epub 2018 Mar 28.

Supplemental Content

Loading ...
Support Center